HC Wainwright & Co. Reiterates Buy on Microbot Medical, Maintains $8 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju reiterated a Buy rating on Microbot Medical (NASDAQ:MBOT) and maintained an $8 price target.
June 26, 2023 | 8:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Raghuram Selvaraju reiterated a Buy rating on Microbot Medical (NASDAQ:MBOT) and maintained an $8 price target.
The reiteration of a Buy rating and maintenance of an $8 price target by HC Wainwright & Co. analyst Raghuram Selvaraju is a positive signal for Microbot Medical (NASDAQ:MBOT). This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100